Stockscreener 앱 받기
12.71
1.03%
0.13
시간 외 거래:
12.71
Niagen Bioscience Inc 주식(NAGE)의 최신 뉴스
Niagen Bioscience (NASDAQ:NAGE) Shares Down 2.4%Should You Sell? - MarketBeat
Market Participants Recognise Niagen Bioscience, Inc.'s (NASDAQ:NAGE) Revenues Pushing Shares 29% Higher - simplywall.st
Niagen Bioscience (NASDAQ:NAGE) Lowered to "Buy" Rating by Wall Street Zen - MarketBeat
Niagen Bioscience (NASDAQ:NAGE) Price Target Raised to $16.00 - MarketBeat
Niagen Bioscience (NASDAQ:NAGE) Downgraded to Buy Rating by Wall Street Zen - Defense World
Niagen Bioscience (NASDAQ:NAGE) Sets New 12-Month High After Analyst Upgrade - MarketBeat
Niagen Bioscience to Participate in the BIO 2025 International C - GuruFocus
Niagen Bioscience to Participate in the BIO 2025 International Convention - Business Wire
Niagen Bioscience: High Conviction, High Expectations (NASDAQ:NAGE) - Seeking Alpha
Canaccord Genuity Group Issues Positive Forecast for Niagen Bioscience (NASDAQ:NAGE) Stock Price - Defense World
Niagen Bioscience (NAGE): Analyst Reaffirms Buy Rating and Incre - GuruFocus
Niagen Bioscience (NAGE) Gains Boost with Positive Clinical Resu - GuruFocus
Niagen study shows promise for Werner Syndrome treatment By Investing.com - Investing.com South Africa
Niagen Bioscience Announces First-Ever Peer-Reviewed Study Highlighting the Potential of Nicotinamide Riboside (NR) for Werner Syndrome, a Rare Genetic Disorder - Business Wire
Niagen Bioscience Announces First-Ever Peer-Reviewed Study Highl - GuruFocus
Niagen Bioscience stock rises following positive clinical study By Investing.com - Investing.com South Africa
Niagen Bioscience stock rises following positive clinical study - Investing.com Australia
Niagen study shows promise for Werner Syndrome treatment - Investing.com
Niagen Bioscience (NASDAQ:NAGE) Shares Gap Up After Analyst Upgrade - MarketBeat
Niagen Bioscience (NASDAQ:NAGE) Given New $23.00 Price Target at Roth Capital - MarketBeat
Niagen Bioscience (NASDAQ:NAGE) Stock Rating Lowered by Wall Street Zen - Defense World
Niagen Bioscience (NASDAQ:NAGE) Shares Gap Up on Analyst Upgrade - Defense World
Niagen Bioscience (NASDAQ:NAGE) Shares Gap Up Following Analyst Upgrade - Defense World
Roth Capital Reiterates “Buy” Rating for Niagen Bioscience (NASDAQ:NAGE) - Defense World
Niagen Bioscience (NASDAQ:NAGE) Reaches New 12-Month HighWhat's Next? - MarketBeat
Niagen Bioscience (NAGE) Target Price Raised to $23 by Roth Capi - GuruFocus
Niagen Bioscience (NAGE) Receives Price Target Boost from Roth Capital | NAGE Stock News - GuruFocus
What 4 Analyst Ratings Have To Say About Niagen Bioscience - Nasdaq
Niagen Bioscience (NAGE) Target Price Raised to $23 by Roth Capital | NAGE Stock News - GuruFocus
Niagen Bioscience (NASDAQ:NAGE) Trading 8.2% HigherShould You Buy? - MarketBeat
Niagen Bioscience Inc (NASDAQ:NAGE) Q1 2025 Earnings Call Transcript - MSN
Niagen Bioscience to Present at Oppenheimer's 25th Annual Consum - GuruFocus
Niagen Bioscience to Present at Oppenheimer's 25th Annual Consumer Growth and E-Commerce Conference | NAGE Stock News - GuruFocus
Niagen Bioscience to Present at Oppenheimer’s 25th Annual Consumer Growth and E-Commerce Conference - Business Wire
Niagen Bioscience (NASDAQ:NAGE) Reaches New 1-Year HighHere's What Happened - MarketBeat
Niagen Bioscience (NASDAQ:NAGE) Now Covered by Canaccord Genuity Group - MarketBeat
Niagen Bioscience (NASDAQ:NAGE) Coverage Initiated by Analysts at Canaccord Genuity Group - Defense World
Canaccord Genuity Initiates Coverage of Niagen Bioscience (NAGE) with Buy Recommendation - Nasdaq
Canaccord Genuity Initiates Niagen Bioscience at Buy With $13 Price Target - marketscreener.com
Canaccord starts Niagen Bioscience at Buy on ‘unique opportunity’ - TipRanks
Niagen Bioscience (NAGE) Receives Positive Outlook with $13 Pric - GuruFocus
0.68%
0.50%
자본화:
|
볼륨(24시간):